Regulatory
Published · Updated · 1 min read
DEC: safety communication materials on potential risks of vonoprazan
What it means for practice
When prescribing vonoprazan, consider the potential risks described, monitor patients regularly, and report suspected adverse reactions.
Summary
The DEC website hosts communication materials for healthcare professionals on the safety of Heliprozan (vonoprazan). According to the available abstract, the document highlights potential treatment risks and stresses the importance of regular patient monitoring and reporting suspected adverse reactions to support ongoing assessment of the benefit–risk balance.
Risks highlighted
- Neuroendocrine tumors associated with increased gastrin levels.
- Liver function impairment.
- Increased fracture risk.
- Clostridium difficile infections.
- Pneumonia.
The abstract also mentions studies comparing vonoprazan with other proton pump inhibitors and draws particular attention to safety concerns in elderly patients and those with pre-existing conditions. It does not provide the sizes of these populations, event frequencies, risk estimates, or results of individual comparisons.
This account concerns potential risks; the abstract does not provide a specific monitoring schedule or a list of required investigations. Detailed recommendations should be checked against the communication materials.
Source
-
dec.gov.ua. Комунікаційні матеріали для спеціалістів системи хорони здоров’я щодо безпеки застосування лікарського засобу ХЕЛІПРОЗАН (вонопразан).
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
